Valuation: SurModics

Market Cap 427M 373M 343M 320M 606M 40.68B 616M 4.13B 1.6B 19.96B 1.6B 1.57B 68.76B P/E 2023
-292x
P/E 2024 -47.3x
Enterprise Value 420M 367M 337M 315M 596M 40.03B 607M 4.06B 1.57B 19.63B 1.58B 1.54B 67.65B EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 25.17
Extreme 25.17
43
5 years 16
Extreme 16
62.27
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 2025-11-18
Director of Finance/CFO 53 2025-11-18
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 2025-11-18
Director/Board Member 53 2025-11-18
Date Insider Type Main position Quantity % Market Cap.
11-18Issuer sale

Controller/Auditor

24,311 0.1700%
11-18Issuer sale

Head of Human Resources

165,155 1.1551%
11-18Issuer sale

Executive/Senior Manager

171,148 1.1970%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+46.79%+37.27% 615M
+3.49%+2.32%-28.86%-11.02% 161B
+5.04%+3.32%-5.77%-4.53% 101B
+2.80%+3.33%+1.83%+55.31% 56.12B
-1.22%-2.88%+53.69%+49.87% 53.35B
+3.39%+4.43%-10.83%-39.65% 42.13B
+3.50%+14.35% - - 35.29B
+3.47%+3.79%-14.75%-43.91% 26.57B
+0.20%+5.53%+65.33%-3.33% 25.79B
+2.78%+3.61%-8.42%-0.43% 20.69B
Average +2.08%+2.80%+11.00%+4.40% 52.25B
Weighted average by Cap. +2.57%+2.00%-3.20%+1.28%

Financials

2023 2024
Net sales 133M 116M 106M 99.21M 188M 12.62B 191M 1.28B 496M 6.19B 498M 487M 21.33B 126M 110M 101M 94.34M 179M 12B 182M 1.22B 472M 5.89B 473M 463M 20.29B
Net income -1.54M -1.34M -1.23M -1.15M -2.18M -146M -2.22M -14.84M -5.75M -71.72M -5.77M -5.64M -247M -11.54M -10.09M -9.26M -8.64M -16.37M -1.1B -16.65M -112M -43.21M -539M -43.34M -42.4M -1.86B
Net Debt -12.1M -10.57M -9.71M -9.05M -17.17M -1.15B -17.46M -117M -45.31M -565M -45.44M -44.45M -1.95B -6.87M -6M -5.51M -5.14M -9.75M -654M -9.91M -66.37M -25.72M -321M -25.8M -25.23M -1.11B
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock